We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Device for Stroke Rehabilitation

By HospiMedica staff writers
Posted on 06 Apr 2005
A new device helps stroke patients re-learn which part of the brain to activate and re-develop spontaneous muscle control. More...
The device, designed for home therapy, has been cleared by the U.S. Food and Drug Administration (FDA).

The Biomove 3000 system detects extremely small electromyographic (EMG) signals that persist in paralyzed muscles after a stroke and uses these tiny signals to initiate an electrical stimulation impulse to the muscles, resulting in actual muscle movement by the patient. If regular electrical impulses are not generated or can no longer reach muscles due to stroke damage, normal muscle contraction becomes impossible. The "leftover” EMG signals are often very small and unable to control muscles. This can lead to irreversible damage and loss of muscle function, resulting in paralysis causing a claw hand or dropped foot.

In almost all cases of stroke, there is still a very small amount of electricity that reaches the muscles. These small leftover EMG signals are picked up by stick-on electrodes placed over the paralyzed muscles. The Biomove device then amplifies these small signals and when an internal preset trigger level is reached, the built-in stimulator returns an electrical stimulation impulse to the same muscles. The muscles now respond as originally "instructed” by the patient's own brain signal.

Patients use this method to rehabilitate the muscles of an otherwise paralyzed hand or foot. The Biomove 3000 device was developed by Curatronic Ltd. (Hashmonaim, Israel). This form of stroke rehabilitation is known as EMG-triggered NMES (neuromuscular electrical stimulation).




Related Links:
Curatronic

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.